Document is current

Article History

Received: 19 September 2024

Accepted: 12 June 2025

First Online: 27 June 2025

Declarations

:

: The presented study is a retrospective analysis of pseudonymised reports of adverse drug reactions. According to the local ethics committee of the Medical Faculty of Bonn, no ethics approval is needed for this study (file no. 100/21). The Anaphylaxis Registry was approved by the ethics committee at Charité-Universitätsmedizin Berlin, Germany (EA1/079/06), accredited by the local ethics committees in the participating centres, and is registered on ClinicalTrials.gov (Identifier: NCT05210543).

: Not applicable.

: Not applicable.

: M. Schmid and D. Dubrall. were supported by the ANKA project, which is founded by the Federal Institute for Drugs and Medical Devices and the Institute for Medical Biometry, Informatics and Epidemiology at the university hospital Bonn. M. Worm declares honoraria for lectures and consulting from Novartis Pharma GmbH, Sanofi-Aventis Deutschland GmbH, DBV Technologies S.A, Aimmune Therapeutics UK Limited, Leo Pharma GmbH, AstraZenceca GmbH, ALK-Abelló Arzneimittel GmbH, Lilly Deutschland GmbH, Kymab Limited, Amgen GmbH, Abbvie Deutschland GmbH & Co. KG, Pfizer Pharma GmbH, Mylan Germany GmbH (A Viatris Company), Boehringer Ingelheim Pharma GmbH & Co. KG, GlaxoSmithKline GmbH & Co. KG, Almirall S. A., Amgen GmbH, Pfizer Deutschland GmbH, Bristol-Myers Squibb GmbH & Co. KGaA and FomF GmbH outside submitted work.

: The information and views set out in this manuscript are those of the authors and do not necessarily reflect the official opinion of the Federal Institute for Drugs and Medical Devices.